116 related articles for article (PubMed ID: 2472243)
1. Controversial aspects of cytoreductive surgery in epithelial ovarian cancer.
Hacker NF
Baillieres Clin Obstet Gynaecol; 1989 Mar; 3(1):49-57. PubMed ID: 2472243
[TBL] [Abstract][Full Text] [Related]
2. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
3. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Cancer; 1995 Nov; 76(9):1606-14. PubMed ID: 8635065
[TBL] [Abstract][Full Text] [Related]
4. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Chen J; Tang MQ; Liu Q; Cai SM
J Surg Oncol; 2000 Sep; 75(1):24-30. PubMed ID: 11025458
[TBL] [Abstract][Full Text] [Related]
5. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
[TBL] [Abstract][Full Text] [Related]
6. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
[TBL] [Abstract][Full Text] [Related]
7. Whole abdominal radiotherapy following cytoreductive surgery and chemotherapy in ovarian carcinoma.
Kersh CR; Randall ME; Constable WC; Hahn SS; Taylor PT; Krebs HB; Goplerud DR
Gynecol Oncol; 1988 Sep; 31(1):113-21. PubMed ID: 3410342
[TBL] [Abstract][Full Text] [Related]
8. Cytoreductive surgery combined with organ resection for advanced ovarian carcinoma.
Todo Y; Sakuragi N; Oikawa M; Negishi H; Yamamoto R; Yoshiaki K; Tsumura N; Kawaguchi I; Fujimoto S
Int J Clin Oncol; 2003 Apr; 8(2):90-6. PubMed ID: 12720101
[TBL] [Abstract][Full Text] [Related]
9. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
10. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
11. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
12. [The value of cytoreductive second-look surgery in advanced epithelial ovarian carcinoma].
Sevelda P; Barrada M; Vavra N; Denison U; Schmidl S; Genger H; Salzer H
Wien Klin Wochenschr; 1990 Aug; 102(15):441-3. PubMed ID: 2402929
[TBL] [Abstract][Full Text] [Related]
13. Surgery in ovarian cancer: the concept of cytoreductive surgery.
Peter A; Heintz M
Curr Opin Obstet Gynecol; 1996 Feb; 8(1):8-11. PubMed ID: 8777265
[TBL] [Abstract][Full Text] [Related]
14. Advanced ovarian cancer. Debulking and intervention surgery.
Hacker NF; van der Burg ME
Ann Oncol; 1993; 4 Suppl 4():17-22. PubMed ID: 8312196
[TBL] [Abstract][Full Text] [Related]
15. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
Gynecol Oncol; 2000 Aug; 78(2):171-5. PubMed ID: 10926798
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
17. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
Chang SJ; Hodeib M; Chang J; Bristow RE
Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
[TBL] [Abstract][Full Text] [Related]
18. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
19. [The role of surgery for advanced epithelial ovarian cancer].
Hatae M; Onishi Y; Nakamura T; Wada T
Gan To Kagaku Ryoho; 1998 Jan; 25(2):201-7. PubMed ID: 9474929
[TBL] [Abstract][Full Text] [Related]
20. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
